Lexeo Therapeutics, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Lexeo is a clinical-stage genetic medicine company developing gene therapies; it has no approved products and has generated no product revenue.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $15.7 million | $16.4 million |
| General and administrative expense | $7.5 million | $2.9 million |
| Total operating expenses / operating loss | $23.3 million | $19.3 million |
| Interest income | $1.7 million | $0.7 million |
| Net loss | $21.7 million | $18.7 million |
| Net loss per share, basic and diluted | $0.77 | $11.58 |
| Net cash used in operations | $14.9 million | $18.4 million |
At March 31, 2024, cash and cash equivalents were $195.1 million, versus $121.5 million at year-end 2023; restricted cash was $3.3 million. Total assets were $213.2 million, total liabilities $30.3 million, and stockholders’ equity $183.0 million. Liabilities primarily included lease obligations: $9.6 million operating and $1.7 million finance lease liabilities. The filing reports no conventional debt balance.
Cash, cash equivalents and restricted cash increased $73.6 million during the quarter, principally due to $88.8 million net proceeds from a March private placement, partly offset by operating and investing outflows. The placement issued 6.28 million shares at $15.13 per share; gross proceeds were approximately $95.0 million. No profit margin is meaningful given the absence of revenue and ongoing operating losses.
Material changes versus the prior period
- Net loss increased $3.0 million year over year as total operating expenses rose $4.0 million, partly offset by higher interest income.
- R&D expense declined $0.7 million. The reduction reflected the absence of a $3.5 million Adverum milestone paid in Q1 2023 and lower preclinical costs, partly offset by increased employee and stock-based compensation, CMC and clinical-trial costs.
- G&A expense increased $4.7 million, mainly from legal costs, compensation and public-company audit, accounting, insurance and professional fees.
- Stock-based compensation increased to $2.3 million from $0.4 million.
Outlook, commentary and risks
- Management expects substantial losses and negative operating cash flows for the foreseeable future, with R&D, G&A and capital expenditures expected to increase. It estimates current funds can support planned operating expenses and capital requirements into 2027; the financial-statement note more conservatively states funds are sufficient for at least 12 months from issuance.
- Lexeo expects additional interim data from LX2006 in mid-2024; cohort 1 data from the LX2020 Phase 1/2 trial in the second half of 2024; and additional LX1001 interim data in the second half of 2024. LX2006 has shown increased cardiac frataxin expression in biopsies from three patients; prior LX1001 first-cohort observations included increased APOE2 expression and a favorable trend in Alzheimer’s biomarkers. These are interim observations, not proof of efficacy.
- Key risks include clinical failure or delays, gene-therapy safety and manufacturing challenges, patient recruitment, reliance on third parties and academic licensors, need for future financing and potential dilution. The company disclosed hepatocellular carcinoma cases in a preclinical LX2006 mouse study; it notes the relevance to human risk is uncertain.
- Rocket Pharmaceuticals’ lawsuit alleges misappropriation of confidential information and seeks unspecified damages and an injunction affecting cardiac gene-therapy work. Lexeo’s motion to dismiss is fully briefed and pending; the company cannot estimate potential loss.
- Subsequent events: Lexeo entered new or amended UCSD sponsored research agreements in April 2024. A new Cornell license agreement for FA cardiomyopathy technology includes a $0.6 million license/data transfer fee, up to $2.1 million in regulatory milestones, up to $100 million in commercial milestones and low-single-digit royalties.
Important facts for investors to verify
- Whether clinical readouts arrive on the stated timelines and whether complete, audited data support the preliminary biomarker observations.
- Cash burn, cash runway assumptions and the difference between the “into 2027” outlook and the note’s “at least 12 months” statement.
- Progress and costs of clinical trials, CMC work and other development programs, including any changes to trial plans or funding needs.
- Developments in the Rocket litigation, including potential effects on costs, programs or operations.
- Share dilution from equity compensation and future financing; common shares outstanding were 32.9 million at March 31, 2024.